Radiant Biotherapeutics
PrivateLast Round
Series A
Sep 11, 2024
Est. Valuation
$65M
Total Funding Raised
$45.17M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Radiant Biotherapeutics operates in Healthcare & Life Sciences and is based in Toronto. Its latest recorded funding round was a Series A round in September 2024.
Radiant Biotherapeutics is a biotechnology company that develops a modular multi-valent and multi-specific platform to create potent biologics for the treatment of cancer, autoimmune disorders, and infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Radiant Biotherapeutics Comparables
Compare Radiant Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tentarix Biotherapeutics | 82% | |
| Invenra | 79% | |
| EpimAb Biotherapeutics | 77% |
For institutional investors. Book with your work email.
Radiant Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 11, 2024 | ||||
| Grant | Dec 20, 2023 | ||||
| Seed | Apr 25, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Radiant Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Aberdeen Group plc | Series A |
| Amplitude Ventures | Series A, Seed |
| Business Development Bank of Canada (BDC Capital) | Series A |
| BDC Capital | Series A |
| Gates Foundation | Series A |
| The Bill & Melinda Gates Foundation Trust | Grant, Series A |
| Alexandria Venture Investments | Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 90% MoM.
- Oct 3, 2025
New data from lead oncology program to be presented at SITC 2025.
For institutional investors. Book with your work email.
Radiant Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Radiant Biotherapeutics's valuation, stock price, and market status.
Is Radiant Biotherapeutics a public or private company?
Radiant Biotherapeutics is a private company.
What is the current stock price of Radiant Biotherapeutics?
Radiant Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Radiant Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Radiant Biotherapeutics worth (valuation)?
Radiant Biotherapeutics's valuation is estimated at $65.0M based on funding round data.
Can I buy Radiant Biotherapeutics stock?
Radiant Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Radiant Biotherapeutics's last funding round?
Radiant Biotherapeutics's most recent funding round was Series A on September 11, 2024.
Who are the main investors in Radiant Biotherapeutics?
Key investors in Radiant Biotherapeutics include Amplitude Ventures, Gates Foundation, The Bill & Melinda Gates Foundation Trust.
Will Radiant Biotherapeutics IPO soon?
No public IPO plans have been announced for Radiant Biotherapeutics.
How can I track Radiant Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Radiant Biotherapeutics's shares on secondary markets.